Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. - Wikidata - awgldk - TriplyDB

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

http://www.wikidata.org/entity/Q40550062

about

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy.Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonography Estimation of intra-operator variability in perfusion parameter measurements using DCE-US.Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling.The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts.Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.Dependence of DCE-MRI biomarker values on analysis algorithm.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Detecting microvascular changes in the mouse spleen using optical computed tomography.Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients.Intravoxel Incoherent Motion MR Imaging in the Head and Neck: Correlation with Dynamic Contrast-Enhanced MR Imaging and Diffusion-Weighted Imaging.Tumour vascular disrupting agents: combating treatment resistance.Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.Imaging tumour physiology and vasculature to predict and assess response to heat.An update on the clinical development of drugs to disable tumor vasculature.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.Imaging analysis of the in vivo bioreactor: a preliminary study.Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.

P2860

Q27346895-D2C6A418-6E4E-4E51-A4C0-D7D7CF5BB5B2 Q30460977-F25D664D-3FA0-416A-9E6B-F45EC0733A48 Q30464680-74974E53-C59A-40DE-93F3-B05C6D52C8A2 Q30475764-72E812DA-E532-4096-8D35-4A660DE51F62 Q30810422-07F8AB92-A287-44B0-A24F-B07B52B87092 Q31049713-AE39C72D-4BBA-448D-8CDC-8BC3333F6019 Q33217481-D81C85AA-8DDD-418C-98A0-ACD6235A48C0 Q33286035-3E9449F5-268C-4F6B-B987-89FFDC66E6D4 Q33474971-A9E75BE0-E781-4156-B9D7-C621FD34F774 Q33510695-338E11E9-8F7E-474A-90A0-478BC848E62B Q33863907-795DB14B-035B-401E-8E07-19C72DA33DD7 Q34145257-6C415CC1-7D01-4826-AD3C-B375E09B391F Q34367593-0C83DBEA-C2C8-48FB-8FD9-977AE58A75D8 Q34538659-D7745BBE-E3DB-4BD8-B378-B1612AEF5CFA Q34633674-228AAA51-4941-4475-A1F5-3B3B1FA070BD Q35052189-41077450-F688-466A-8870-8CB4AEEB8E90 Q35170356-319ECA17-5932-4B74-AC38-D6DCA5C86CBB Q35711964-91516CC4-D66E-4512-BA8E-F2432682496B Q35879814-91179FE8-5750-453C-B55A-0414CF2A6D66 Q35974239-F5258036-69D9-4354-A1C0-8B245B1CAB94 Q36611627-453B5A03-C82A-41A3-8E04-3CF15593B68E Q36613314-47A2A02E-D165-4809-AB64-E43F463387A1 Q36614213-87C0C3FC-7CC9-4B92-B68D-3F10B17C9957 Q36615531-6F4A2E62-5D5A-4442-B9FB-B82AC4B5F0B2 Q36702766-100241F6-2616-4D3E-8BB4-651B3EB54E25 Q36785948-063D4685-E8B4-4DF2-84D6-9914752C5D19 Q36993641-79197561-AA52-4284-AB33-2FF332F50EFC Q37223087-B27E4003-5ADD-4D06-AE4D-79C513646FDA Q37280244-79EF9A2E-D00B-4134-BDF7-BCC74510D519 Q37316228-55D54074-ED03-4049-81AE-CF354AB167C4 Q37344824-4E8E93D0-2DFF-45EB-8F7D-99498D6DDE6B Q37418739-1D454727-5E6C-40E0-B6E1-F5368DDBFABE Q37592390-7D4DA49B-5DEC-4098-9655-0D8CA275949D Q37730090-DC64F8FC-7459-4B36-BAAC-91B849F95112 Q38088732-B0895898-EA3C-4F28-B751-E9F620F5ABAE Q38168371-023809A8-C4CB-482C-AA70-865A12AA000E Q39657204-DC26A3F3-DF7F-4AE7-B922-74B7AEBF7F08 Q40087261-762C8B4F-DC1E-4052-89F8-97D9E28D9642 Q41552582-143B40C6-9B49-4CE0-9A36-7895FBB1EE9F Q42497254-667D7A53-A5FA-43A8-AD74-1AA13BE4B507

P2860

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

http://www.wikidata.org/entity/Q40550062

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.

@en

type

label

Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.

@en

prefLabel

Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.

@en

P1433

Q40550062-C42704B1-065E-4544-80B4-E1777C754034

P1476

Q40550062-E6107C4F-135A-4DCC-87A1-7F0B9405FEF7

P2093

Q40550062-22932CBD-C7F6-4219-8D6E-3F056A09C7B9

Q40550062-2D83777B-95C4-40EE-AF0E-214495A74094

Q40550062-30A1CEB7-6ADF-4D61-9702-E114CE190F06

Q40550062-698D1DE8-6632-4702-A543-99949BF4F93F

Q40550062-7346B462-A520-493E-80F8-3300FB4E5AB7

Q40550062-9D844ACE-0C62-4D8F-AEC4-29998F15A413

Q40550062-A34028AC-C1D9-463A-A882-104F87D113F7

Q40550062-B16BC633-00D3-44EA-B64A-2A6BEB9D2763

Q40550062-B500941B-A108-4D27-993A-DFB2D2981CB5

Q40550062-D9D9B45A-7F47-4FD7-9D1A-3485EB084E11

P304

Q40550062-61A5C27C-3154-4EEB-9DFA-40BFC0D62153

P31

Q40550062-0F5F2EC3-3668-4DBE-AC93-DE41A9F5DF9A

P356

Q40550062-98566539-8226-42C6-9156-BBE942824A1A

P407

Q40550062-D9D0EF0A-2BED-41AD-B527-08757F87E974

P433

Q40550062-AAD51B2F-388B-476B-9B5B-196529CF113D

P478

Q40550062-517C5B8E-8811-4046-9B96-FC2192A0C73D

P577

Q40550062-C2D2F7D8-86F8-4EA2-8619-61E06984BAF2

P698

Q40550062-BC1A53D1-5B55-4ACF-9DEC-0E3DFE691305

P356

1078-0432.CCR-03-0417

P1433

Clinical Cancer Research

P1476

Magnetic resonance imaging mea ...... scular-targeting agent ZD6126.

@en

P2093

Anderson J Ryan

http://www.w3.org/2001/XMLSchema#string

Andrew Stone

http://www.w3.org/2001/XMLSchema#string

Catherine Wheeler

http://www.w3.org/2001/XMLSchema#string

David C Blakey

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Evelhoch

http://www.w3.org/2001/XMLSchema#string

Joanna Leadbetter

http://www.w3.org/2001/XMLSchema#string

John C Waterton

http://www.w3.org/2001/XMLSchema#string

Lisa Polin

http://www.w3.org/2001/XMLSchema#string

Patricia M LoRusso

http://www.w3.org/2001/XMLSchema#string

Peter Langmuir

http://www.w3.org/2001/XMLSchema#string

P304

3650-3657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-03-0417

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15173071

http://www.w3.org/2001/XMLSchema#string